FDA grants breakthrough therapy designation to Enhertu for high-risk early breast cancer
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy
Full approval will depend on verification of clinical benefit in a confirmatory trial
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
The system is intended for some of the tiniest patients—premature infants weighing as little as two pounds
Using a combination of blood and faecal samples, the service examines key biomarkers, including hereditary genetic status
The company along with its subsidiaries has overall bed capacity of 8800+ beds as on 30th September, 2025
The initiative is focused on a problem that continues to plague cancer outcomes in India
Subscribe To Our Newsletter & Stay Updated